| 1 |
NCT03316599 |
Recruiting |
Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer |
|
- Drug: Gemcitabine
- Drug: Nab-paclitaxel
- Drug: Ficlatuzumab
|
Interventional |
Phase 1 |
- Dana-Farber Cancer Institute
- AVEO Pharmaceuticals, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The Maximum Tolerated Dose of ficlatuzumab when administered in combination with gemcitabine and nab-paclitaxel
- The response rate in this population of patients.
- The progression free survival in this population of patients.
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT03316599 |
17-406 |
|
January 17, 2018 |
November 30, 2020 |
November 30, 2023 |
October 20, 2017 |
January 23, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
| 2 |
NCT03435289 |
Recruiting |
A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer |
- Pancreatic Cancer
- Metastatic Pancreatic Cancer
|
- Drug: CPI 613 in Combination With Gemcitabine and Nab-paclitaxel
|
Interventional |
Phase 1 |
- Atlantic Health System
- Rafael Pharmaceuticals Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The maximally tolerated dose of CPI 613 combined with Gemcitabine and nab-paclitaxel
- The number of participants with treatment related adverse events as assessed by CTCAE v 4.0
- The number of participants with complete or partial response
|
24 |
All |
18 Years and older (Adult, Senior) |
NCT03435289 |
GA CPI 613 |
|
October 19, 2017 |
November 2018 |
January 2019 |
February 16, 2018 |
February 16, 2018 |
|
- Morristown Medical Center
Morristown, New Jersey, United States - Overlook Medical Center
Summit, New Jersey, United States
|
| 3 |
NCT03060720 |
Recruiting |
Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy |
|
|
Observational |
|
- Dana-Farber Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Other
- Time Perspective: Prospective
|
- We will measure clinical factors (e.g. # of PDAC patients with a personal history of x,y,z; # of PDAC patients with a family history of x,y,z; # PDAC patients with a germline mutation in x,y,z) so as to develop a risk assessment tool
- Evaluate Patient Experience With Genetic Testing
- Summarize patient satisfaction with Genetic counseling
- Number of patients who disclose genetic testing results to relatives
|
375 |
All |
18 Years and older (Adult, Senior) |
NCT03060720 |
16-448
P50CA127003 |
|
February 24, 2017 |
February 2020 |
February 2022 |
February 23, 2017 |
February 1, 2018 |
|
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
| 4 |
NCT02459652 |
Active, not recruiting |
Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer |
|
- Drug: S-1
- Radiation: Radiation Therapy
|
Interventional |
Phase 2 |
- Japan Adjuvant Study Group of Pancreatic Cancer
- Japan Agency for Medical Research and Development
- Pharma Valley Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- R0 resection rate
- Overall survival
- Disease-free survival
- (and 6 more...)
|
50 |
All |
20 Years to 75 Years (Adult, Senior) |
NCT02459652 |
JASPAC 05 |
|
September 2012 |
April 2016 |
September 2018 |
June 2, 2015 |
June 29, 2016 |
|
- Aichi Cancer Center
Nagoya, Aichi, Japan - Nagoya University Hospital
Nagoya, Aichi, Japan - Hirosaki University Hospital
Hirosaki, Aomori, Japan - (and 19 more...)
|
| 5 |
NCT02841436 |
Active, not recruiting |
A Clinical Research About Using Irreversible Electroporation to Treat Locally Advanced Pancreatic Cancer |
|
- Device: Irreversible Electroporation (IRE) System
|
Interventional |
Not Applicable |
- National Taiwan University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tumor response
- Eastern Cooperative Oncology Group (ECOG) evaluation
- Haematology test
- (and 4 more...)
|
40 |
All |
20 Years to 75 Years (Adult, Senior) |
NCT02841436 |
201210008DIC |
|
November 2012 |
October 2018 |
October 2018 |
July 22, 2016 |
February 23, 2017 |
|
|
| 6 |
NCT02550847 |
Unknown † |
Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer |
|
- Device: The imaging biomarkers determined by MR-PET
|
Observational |
|
- National Taiwan University Hospital
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- The tumor recurrence rate after operation at 6 months
- The overall survival after operation at 6 months
|
100 |
All |
20 Years to 90 Years (Adult, Senior) |
NCT02550847 |
201407052MINC |
|
August 2014 |
April 2016 |
August 2016 |
September 16, 2015 |
April 14, 2016 |
|
- National Taiwan University Hospital
Taipei, Taiwan
|
| 7 |
NCT01867892 |
Enrolling by invitation |
A Phase II Study of Locally Advanced Pancreatic Cancer |
|
- Drug: ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT
- Drug: ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT
|
Interventional |
Phase 2 |
- National Health Research Institutes, Taiwan
- National Taiwan University Hospital
- National Cheng-Kung University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- the response rate, disease control rate, overall survival, and patients' quality of life.
|
86 |
All |
20 Years to 70 Years (Adult, Senior) |
NCT01867892 |
T2212 |
|
June 2013 |
May 2018 |
May 2019 |
June 4, 2013 |
June 4, 2013 |
|
|
| 8 |
NCT03497819 |
Active, not recruiting
New |
Autologous CARTmeso/19 Against Pancreatic Cancer |
|
- Biological: CARTmeso CART19
|
Interventional |
Early Phase 1 |
- First Affiliated Hospital of Wenzhou Medical Univeristy
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The Percentage of Adverse Events (AEs) ≥ grade 3 assessed through MedDra and CTCAE v4.03 [Time frame: from infusion to 3 month afterward]
- Overall Response Rate defined as any improvement measured by imaging following RECIST 1.1 [Time Frame: Day 14 and 1 month after infusion]
|
10 |
All |
18 Years to 65 Years (Adult) |
NCT03497819 |
YXA-meso19 |
|
October 1, 2017 |
October 31, 2019 |
October 31, 2020 |
April 13, 2018 |
April 13, 2018 |
|
- First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
|
| 9 |
NCT01693276 |
Terminated |
Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer |
|
- Drug: Gemcitabine
- Drug: Abraxane
- Radiation: Radiation Therapy
|
Interventional |
Phase 1
Phase 2 |
- Olugbenga Olowokure
- University of Cincinnati
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Increase overall survival
- Rate of local control
|
3 |
All |
18 Years and older (Adult, Senior) |
NCT01693276 |
UCC-GI-01 |
|
September 2012 |
June 2014 |
June 2014 |
September 26, 2012 |
October 26, 2015 |
|
- University of Cincinnati
Cincinnati, Ohio, United States
|
| 10 |
NCT02827201 |
Active, not recruiting |
FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine |
- Metastatic Pancreatic Cancer
|
- Drug: FOLFIRI.3
- Drug: nab-paclitaxel+ gemcitabine
|
Interventional |
Phase 2 |
- Federation Francophone de Cancerologie Digestive
- UNICANCER
- GERCOR - Multidisciplinary Oncology Cooperative Group
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of patients alive without progression 6 months after inclusion
- Overall survival (OS):
- Objective response rate (ORR)
- (and 3 more...)
|
127 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02827201 |
PRODIGE 37 |
FIRGEMAX |
November 2015 |
December 2017 |
December 2020 |
July 11, 2016 |
February 23, 2017 |
|
- CH
Abbeville, France - CH
AIX, France - Clinique de l'Europe
Amiens, France - (and 50 more...)
|
| 11 |
NCT02449967 |
Withdrawn |
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Cancer |
|
- Procedure: interventional therapy
|
Interventional |
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with Adverse events
- Percentage of lesions that show no sign of recurrence 12 months after interventional therapy
- Progress free disease (PFS)
- Overall survival (OS)
|
0 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02449967 |
Pancreatic Cancer HepaSphere |
|
May 2015 |
June 2018 |
June 2020 |
May 21, 2015 |
August 5, 2015 |
|
- Central laboratory in Fuda cancer hospital
Guangzhou, Guangdong, China
|
| 12 |
NCT03180437 |
Recruiting |
Safety and Efficiency of γδ T Cell Against Pancreatic Cancer |
|
- Procedure: Cryosurgery or IRE surgery
- Biological: γδ T cell
- Other: γδ T cells/ A Cryosurgery or IRE
|
Interventional |
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- Jinan University Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Relief degree of tumors
- Progress free survival（PFS）
- Overall survival（OS）
|
30 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03180437 |
Gd T cell and Pancreatic Ca |
|
June 15, 2017 |
June 15, 2018 |
June 15, 2020 |
June 8, 2017 |
June 8, 2017 |
|
- Biotherapy center in Fuda cancer hospital
Guangzhou, Guangdong, China
|
| 13 |
NCT01346410 |
Completed
Has Results |
Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer |
|
- Radiation: Stereotactic Body Radiotherapy
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Local Control Rate
- Late Toxicity Rate
|
1 |
All |
18 Years and older (Adult, Senior) |
NCT01346410 |
08-060 |
|
September 2008 |
July 2012 |
July 2012 |
May 3, 2011 |
February 21, 2018 |
February 21, 2018 |
- St. John's Mercy Medical Center
Saint Louis, Missouri, United States
|
| 14 |
NCT03392571 |
Not yet recruiting |
Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients |
- Resectable Pancreatic Cancer
|
|
Interventional |
Phase 2 |
- Pancreatic Cancer Research Team
- Celgene Inc
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate 2 year survival from date of entry into study
- Determine the number and type of treatment-related adverse events as assessed by CTCAE 4.0
- Histological Response to Pre-Operative Therapy
- (and 5 more...)
|
70 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03392571 |
PCRT 17-001 |
|
February 15, 2018 |
December 30, 2020 |
December 30, 2020 |
January 8, 2018 |
January 8, 2018 |
|
|
| 15 |
NCT01587534 |
Completed |
Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP) |
|
|
Interventional |
Phase 2 |
- National Cancer Center, Korea
- Pharmbio Korea Co., Ltd.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- the change in body weight at eight weeks after the randomisation
- Frequency and intensity of abdominal pain daily
- Frequency of bowel movements per day
|
67 |
All |
18 Years and older (Adult, Senior) |
NCT01587534 |
NCCCTS-11-570 |
|
October 2011 |
December 2014 |
December 2014 |
April 30, 2012 |
April 15, 2015 |
|
- NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong‐gu,
Goyang-si, Gyeonggi-do, Korea, Republic of
|
| 16 |
NCT02767752 |
Recruiting |
Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer |
|
- Dietary Supplement: T-ChOS
- Drug: Gemcitabine
- Dietary Supplement: Placebo
- Drug: Capecitabine
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Disease-free survival (DFS)
- Overall Survival
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Quality of Life
|
180 |
All |
18 Years and older (Adult, Senior) |
NCT02767752 |
GI 1604 |
CHIPAC |
November 2016 |
November 2019 |
November 2021 |
May 10, 2016 |
November 11, 2016 |
|
- Department of Oncology
Herlev, Denmark
|
| 17 |
NCT01423604 |
Completed
Has Results |
Study of Ruxolitinib in Pancreatic Cancer Patients |
|
- Drug: Capecitabine
- Drug: Ruxolitinib
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Overall Survival
- Progression-Free Survival (PFS)
- Objective Response Rate
- (and 2 more...)
|
136 |
All |
18 Years and older (Adult, Senior) |
NCT01423604 |
18424-262 |
RECAP |
July 2011 |
June 2013 |
November 2016 |
August 26, 2011 |
February 12, 2018 |
August 29, 2016 |
- Birmingham, Alabama, United States
- Hot Springs, Arkansas, United States
- Burbank, California, United States
- (and 36 more...)
|
| 18 |
NCT02650804 |
Recruiting |
BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients |
|
- Drug: BPM31510 Nanosuspension Injection
- Drug: Gemcitabine
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR)
- Overall Survival (OS)
- Time to Progression (TTP)
- (and 3 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02650804 |
BPM31510IV-05 |
|
February 2016 |
January 2019 |
January 2019 |
January 8, 2016 |
March 19, 2018 |
|
- Banner Health
Gilbert, Arizona, United States - Mayo Clinic
Phoenix, Arizona, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - (and 7 more...)
|
| 19 |
NCT03192462 |
Recruiting |
TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer |
|
- Biological: multiTAA specific T cells
|
Interventional |
Phase 1
Phase 2 |
- Baylor College of Medicine
- Center for Cell and Gene Therapy, Baylor College of Medicine
- The Methodist Hospital System
- (and 3 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients with treatment related serious adverse events
- Number of patients who received 6 infusions of multiTAA-specific T cells
- Progression Free Survival using the Kaplan-Meier method
- Overall Survival using the Kaplan-Meier method
|
45 |
All |
18 Years and older (Adult, Senior) |
NCT03192462 |
H-40378 TACTOPS |
TACTOPS |
January 18, 2018 |
May 1, 2021 |
November 1, 2025 |
June 20, 2017 |
February 2, 2018 |
|
- Baylor Clinic
Houston, Texas, United States - Houston Methodist Hospital
Houston, Texas, United States - Harris Health System - Smith Clinic
Houston, Texas, United States
|
| 20 |
NCT03374293 |
Recruiting |
Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer |
|
- Radiation: Radiation
- Drug: Anti-PD-1 Antibody
|
Interventional |
Phase 2 |
- Shixiu Wu
- Hangzhou Cancer Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Local control
- Incidence of Treatment-Emergent Adverse Events
- Objective response rate
- Overall survival
|
21 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03374293 |
HangzhouCH10 |
|
December 1, 2017 |
December 31, 2018 |
December 31, 2018 |
December 15, 2017 |
December 15, 2017 |
|
- Hangzhou Cancer Hospital
Hangzhou, Zhejiang, China
|
| 21 |
NCT02934984 |
Recruiting |
Circulating Cell-free Tumor DNA(ctDNA) in Pancreatic Cancer |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Rates of recurrence in pancreatic cancer patients
- Rates of death in pancreatic cancer patients
|
100 |
All |
20 Years to 90 Years (Adult, Senior) |
NCT02934984 |
2016-07-054 |
|
July 2016 |
July 2019 |
January 2020 |
October 17, 2016 |
October 17, 2016 |
|
- Samsung Medical Center
Seoul, Korea, Republic of
|
| 22 |
NCT02050178 |
Completed |
Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer |
- Pancreatic Cancer
- Stage IV Pancreatic Cancer
|
- Drug: OMP-54F28, Nab-Paclitaxel and Gemcitabine
|
Interventional |
Phase 1 |
- OncoMed Pharmaceuticals, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability of OMP-54F28 in combination with nab-paclitaxel and gemcitabine in patients with previously untreated Stage IV pancreatic cancer
- Pharmacokinetics (PK) of OMP-54F28 when administered in combination with nabpaclitaxel and gemcitabine to patients with previously untreated Stage IV pancreatic cancer
|
26 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT02050178 |
54F28-002 |
|
November 2013 |
June 15, 2017 |
June 15, 2017 |
January 30, 2014 |
April 9, 2018 |
|
- USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - University of Colorado Hospital Anschutz Cancer Pavilion
Aurora, Colorado, United States - Indiana University Simon Cancer Center
Indianapolis, Indiana, United States - (and 2 more...)
|
| 23 |
NCT00994721 |
Completed |
A Phase III Study of Pancreatic Cancer |
|
|
Observational |
|
- National Health Research Institutes, Taiwan
- National Taiwan University Hospital
- Chang Gung Memorial Hospital
- (and 6 more...)
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- The primary end-point is recurrence-free survival.
- The secondary end-points are overall survival; local and distant control rate, and the quality of life.
|
147 |
All |
20 Years to 75 Years (Adult, Senior) |
NCT00994721 |
T3207 |
|
February 2009 |
January 2016 |
January 2016 |
October 14, 2009 |
May 4, 2016 |
|
- Chang-Gung Memorial Hospital
Taipei, Taiwan - Mackay Memorial Hospital
Taipei, Taiwan - National Taiwan University Hospital
Taipei, Taiwan
|
| 24 |
NCT02005315 |
Completed |
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer |
- Pancreatic Cancer
- Stage IV Pancreatic Cancer
|
- Drug: Vantictumab
- Drug: Nab-Paclitaxel
- Drug: Gemcitabine
|
Interventional |
Phase 1 |
- OncoMed Pharmaceuticals, Inc.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1b: Safety and tolerability of vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated Stage IV pancreatic cancer
- Pharmacokinetics (PK) of vantictumab when administered in combination with nab-paclitaxel and gemcitabine to patients with previously untreated Stage IV pancreatic cancer
|
30 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT02005315 |
18R5-003 |
|
September 2013 |
October 2017 |
November 2017 |
December 9, 2013 |
January 24, 2018 |
|
- USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - University of Colorado Hospital Anschutz Cancer Pavillion
Aurora, Colorado, United States - Indiana University Simon Cancer Center
Indianapolis, Indiana, United States - (and 2 more...)
|
| 25 |
NCT01396681 |
Completed |
Adjuvant Gemcitabine and Cisplatin Followed by Chemoradiation for Resected Pancreatic Cancer |
|
- Drug: gemcitabine and cisplatin
|
Interventional |
Phase 2 |
- Seoul National University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- recurrence/metastasis free survival
- 2 year survival rate
- Overall survival
- (and 2 more...)
|
70 |
All |
18 Years and older (Adult, Senior) |
NCT01396681 |
H-0412-138-006 |
|
December 2004 |
June 2011 |
June 2011 |
July 19, 2011 |
July 19, 2011 |
|
- Seoul National University Bundang Hospital
Seongnam, Korea, Republic of - Seoul National University Hospital
Seoul, Korea, Republic of
|
| 26 |
NCT01333631 |
Unknown † |
Valproic Acid With Chemoradiotherapy for Pancreatic Cancer |
|
|
Interventional |
Phase 2 |
- Soroka University Medical Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of the patients with side effects
- Number of the patients survived
|
20 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01333631 |
SOR513511CTIL |
|
June 2011 |
June 2013 |
July 2015 |
April 12, 2011 |
April 12, 2011 |
|
|
| 27 |
NCT01505413 |
Completed |
Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer |
|
- Drug: Erlotinib
- Drug: Gemcitabine
- Drug: Oxaliplatin
|
Interventional |
Phase 2 |
- Soonchunhyang University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate
- disease control rate(SD,PR,CR)
- Overall survival
|
33 |
All |
18 Years and older (Adult, Senior) |
NCT01505413 |
Yun-11349 |
GEMOX-T |
January 2011 |
December 2013 |
March 2014 |
January 6, 2012 |
April 3, 2014 |
|
- Soonchunhyang University Bucheon Hospital
Bucheon, Gyeonggi, Korea, Republic of
|
| 28 |
NCT02734680 |
Recruiting |
IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer |
|
- Radiation: Concurrent chemoradiotherapy(CCRT)
- Radiation: Stereotactic Radiotherapy(SBRT)
- Drug: S-1
|
Interventional |
Not Applicable |
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overal survival
- Disease-specific survival
- Progression-free survival
- Local control rate
|
70 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02734680 |
LC2015L11 |
IFCSLAPC |
February 2016 |
February 2018 |
February 2019 |
April 12, 2016 |
April 11, 2017 |
|
- National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing, China
|
| 29 |
NCT02128100 |
Recruiting |
Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer |
- Pancreatic Cancer Non-resectable
|
- Drug: Folfirinox
- Radiation: Stereotactic Body Radiation Therapy
|
Interventional |
Phase 2 |
- University of Louisville
- James Graham Brown Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with Adverse Event(s) as a Measure of Safety and Tolerability
- Overall Response Rate for Participants
|
28 |
All |
18 Years and older (Adult, Senior) |
NCT02128100 |
BCC-RAD-13
IRB # 14.0XXX |
BCC-RAD-13 |
May 2014 |
May 2018 |
May 2018 |
May 1, 2014 |
January 5, 2018 |
|
- James Graham Brown Cancer Center
Louisville, Kentucky, United States - James Graham Brown Cancer Center
Louisville, Kentucky, United States
|
| 30 |
NCT00897832 |
Completed |
Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer |
|
- Other: laboratory biomarker analysis
|
Observational |
|
- Vanderbilt-Ingram Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Determination if a method of extracting and identifying biomarkers from tissues of the quantity obtained from typical biopsy can be applied in the setting of pancreatic cancer
|
50 |
All |
Child, Adult, Senior |
NCT00897832 |
VICC GI 0666
P30CA068485
VU-VICC-GI-0666
VU-VICC-061225 |
|
January 2007 |
December 2007 |
December 2007 |
May 12, 2009 |
March 5, 2013 |
|
- Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee, United States - Vanderbilt-Ingram Cancer Center at Franklin
Nashville, Tennessee, United States - Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
|
| 31 |
NCT00897741 |
Completed |
Gene Expression Profiles in Patients With Metastatic Pancreatic Cancer |
|
- Genetic: microarray analysis
- Other: laboratory biomarker analysis
|
Observational |
|
- Barbara Ann Karmanos Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
10 |
All |
Child, Adult, Senior |
NCT00897741 |
CDR0000482353
P30CA022453
WSU-D-2841
WSU-HIC-091504M1E |
|
December 2004 |
May 2008 |
March 2009 |
May 12, 2009 |
February 11, 2014 |
|
- Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
|
| 32 |
NCT02894944 |
Recruiting |
Clinical Trial Phase I for Theragene in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer |
|
- Biological: Theragene®,Ad5-yCD/mutTKSR39rep-ADP
|
Interventional |
Phase 1 |
- Seoul National University Hospital
- NewGenPharm Inc.
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with treatment-related adverse events assessed by CTCAE v4.03
- Tumor response
- Time to disease progression
- (and 2 more...)
|
9 |
All |
18 Years to 74 Years (Adult, Senior) |
NCT02894944 |
SNUBH-IMGPB-2016-02 |
Theragene |
August 2016 |
July 2018 |
July 2018 |
September 9, 2016 |
October 11, 2017 |
|
- Seoul National University Bundang Hospital
Seongnam, Gyeonggi-do, Korea, Republic of
|
| 33 |
NCT02718859 |
Unknown † |
Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer |
|
- Biological: NK cells
- Procedure: irreversible electroporation (IRE )
|
Interventional |
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- Shenzhen Hank Bioengineering Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relief degree
- Progress free survival（PFS）
- Overall survival（OS）
|
60 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02718859 |
NK-pancre |
|
March 2016 |
March 2017 |
March 2017 |
March 24, 2016 |
July 19, 2016 |
|
- Central laboratory in Fuda cancer hospital
Guangzhou, Guangdong, China
|
| 34 |
NCT00837135 |
Withdrawn |
GI-4000 With Adoptive Transfer in Pancreatic Cancer |
|
- Other: Screening
- Biological: GI-4000 Vaccine
- Biological: GI-4000 Vaccine + Activated T Cells
- Biological: Surgical Evaluation after Vaccine #4
|
Interventional |
Phase 1 |
- University of Pennsylvania
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate the feasibility of incorporating GI-4000 vaccine and activated T-cell infusion into a regimen of chemotherapy, radiation, and surgical resection to treat locally advanced pancreatic cancer.
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT00837135 |
806693
UPCC 03207 |
|
January 2008 |
October 2009 |
October 2009 |
February 5, 2009 |
August 17, 2016 |
|
|
| 35 |
NCT00965718 |
Completed
Has Results |
Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer |
|
- Biological: Activated T lymphocyte
|
Interventional |
Phase 2 |
- Green Cross Cell Corporation
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease Control Rate
- Stable Disease(SD)
- Progressive Disease(PD)
- (and 4 more...)
|
20 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00965718 |
ILC-IIT-01 |
|
September 2009 |
December 2010 |
December 2010 |
August 26, 2009 |
December 5, 2017 |
September 16, 2014 |
- Yonsei medical center
Seoul, Korea, Republic of
|
| 36 |
NCT02079623 |
Unknown † |
Electroporation (NanoKnife) as Treatment for Advanced Pancreatic Cancer |
|
- Procedure: Electroporation/ Nano knife treatment
- Device: NanoKnife
|
Interventional |
Phase 3 |
- Aalborg Universitetshospital
- Uppsala University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tumor response
- CA-19-9
- Overall survival
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT02079623 |
PCaNanoK |
NanoKnife |
November 2013 |
November 2015 |
November 2015 |
March 6, 2014 |
March 6, 2014 |
|
- Surgical Department of Gastroenterology, Aalborg University Hospital
Aalborg, Nothern Jutland, Denmark
|
| 37 |
NCT00810719 |
Completed
Has Results |
Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer |
|
- Drug: Erlotinib
- Drug: gemcitabine
|
Interventional |
Phase 2 |
- University of California, Davis
- National Cancer Institute (NCI)
- Genentech, Inc.
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival
- Response Rate
- Overall Survival
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT00810719 |
UCDCC#211
232494
OSI 4132s
P30CA093373 |
|
April 2009 |
January 2013 |
December 2013 |
December 18, 2008 |
January 10, 2018 |
March 7, 2017 |
- USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, United States - University of California Davis Cancer Center
Sacramento, California, United States
|
| 38 |
NCT03187028 |
Recruiting |
Diet and Exercise After Pancreatic Cancer |
|
- Behavioral: Diet Only
- Behavioral: Diet + Exercise
|
Interventional |
Not Applicable |
- University of Alabama at Birmingham
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Feasibility - Recruitment
- Feasibility - Adherence to study protocol activities
- Feasibility - Attrition rates
- (and 12 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT03187028 |
F141218007 |
PACE |
August 3, 2017 |
August 31, 2018 |
August 31, 2019 |
June 14, 2017 |
January 3, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States
|
| 39 |
NCT00636883 |
Terminated |
Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer |
|
|
Interventional |
Phase 2 |
- National Guard Health Affairs
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate (partial and complete response, stable disease, and progressive disease)
- Overall survival
|
9 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00636883 |
RC07/031 |
GEMOX-T |
January 2008 |
July 2012 |
July 2012 |
March 17, 2008 |
January 22, 2014 |
|
- National Guard Health Affairs
Riyadh, Saudi Arabia
|
| 40 |
NCT02981641 |
Recruiting |
IORT Versus CCRT for Pancreatic Cancer |
- Pancreatic Cancer Stage IV
|
- Radiation: Intraoperative radiotherapy (IORT)
- Drug: Sequential chemotherapy
- Radiation: Three dimensional conformal radiation therapy (3D-CRT)
- Drug: Concurrent chemotherapy
|
Interventional |
Not Applicable |
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overal survival
- Disease-specific survival
- Progression-free survival
- Local control rate
|
100 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02981641 |
2012AA022701 |
IVCPC |
December 2015 |
December 2016 |
December 2018 |
December 5, 2016 |
December 5, 2016 |
|
- CancerIHCAMS
Beijing, Beijing, China
|
| 41 |
NCT03117920 |
Recruiting |
A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer |
|
|
Interventional |
Phase 2 |
- Queen Mary University of London
- Minneamrita Therapeutics LLC
- Barts & The London NHS Trust
- Translational Genomics Research Institute
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease Control rate (DCR)
- Progression Free Survival (PFS)
- Incidence of adverse events
- (and 5 more...)
|
35 |
All |
18 Years and older (Adult, Senior) |
NCT03117920 |
Minnelide002 |
MinPAC |
April 10, 2017 |
May 15, 2018 |
February 15, 2019 |
April 18, 2017 |
September 14, 2017 |
|
- HonorHealth Research Institute
Scottsdale, Arizona, United States - Moores UC San Diego Cancer Center
La Jolla, California, United States - University of Pennsylvania
Philadelphia, Pennsylvania, United States - Barts Health NHS Trust
London, United Kingdom
|
| 42 |
NCT01327794 |
Completed |
Relationship Between Vitamin D Biomarkers and Survival in Blood Samples From Patients With Advanced Pancreatic Cancer |
|
- Genetic: polymorphism analysis
- Other: immunologic technique
- Other: laboratory biomarker analysis
- Other: medical chart review
|
Observational |
|
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Association between 25(OH)D level and OS
- Association between 25(OH)D level and PFS
|
265 |
All |
18 Years and older (Adult, Senior) |
NCT01327794 |
CALGB-151006
U10CA031946
CDR0000698059 |
|
June 2011 |
August 2014 |
August 2014 |
April 4, 2011 |
June 29, 2016 |
|
- Charles R. Wood Cancer Center at Glens Falls Hospital
Glens Falls, New York, United States
|
| 43 |
NCT01273805 |
Completed
Has Results |
Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer |
|
|
Interventional |
Phase 2 |
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Massachusetts General Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 2-month Progression-Free Survival Rate
- Biochemical Response Rate
- Tumor Response Rate
- (and 3 more...)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT01273805 |
10-310 |
|
January 2011 |
January 2013 |
February 2014 |
January 11, 2011 |
June 14, 2017 |
June 14, 2017 |
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States - Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 44 |
NCT02352337 |
Active, not recruiting |
First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem |
- Metastatic Pancreatic Cancer
|
- Drug: FOLFIRINOX
- Drug: LV5FU2
- Drug: FOLFIRI.3
- Drug: Gemcitabine
|
Interventional |
Phase 2 |
- Federation Francophone de Cancerologie Digestive
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of patients alive and without radiological and/or clinical progression
- Duration of disease control
- Toxicity (NCI-CTC V4.0)
- (and 3 more...)
|
276 |
All |
18 Years and older (Adult, Senior) |
NCT02352337 |
PRODIGE35 |
PANOPTIMOX |
December 23, 2014 |
December 2017 |
June 2019 |
February 2, 2015 |
February 23, 2017 |
|
- CH
Abbeville, France - CHU
Amiens, France - CHU
Angers, France - (and 62 more...)
|
| 45 |
NCT00544908 |
Terminated
Has Results |
Dasatinib in Treating Patients With Stage IV Pancreatic Cancer |
|
- Drug: dasatinib
- Other: immunoenzyme technique
- Other: immunohistochemistry staining method
- (and 2 more...)
|
Interventional |
Phase 2 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free Survival (PFS) Rate at 4 Months
- Response Rate
|
7 |
All |
18 Years and older (Adult, Senior) |
NCT00544908 |
07024
P30CA033572
CHNMC-07024
BMS-CA180-114
CDR0000570288 |
|
September 2007 |
October 2012 |
|
October 16, 2007 |
October 5, 2015 |
September 17, 2015 |
- City of Hope Comprehensive Cancer Center
Duarte, California, United States - City of Hope Medical Group
Pasadena, California, United States
|
| 46 |
NCT01898741 |
Unknown † |
Cone-beam CT Guided Stereotactic Radiation Therapy for Locally Advanced Pancreatic Cancer |
|
- Radiation: 24 Gy in 3 fractions
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT01898741 |
UMCU-12-628 |
|
July 2013 |
July 2016 |
July 2016 |
July 12, 2013 |
February 3, 2015 |
|
- University Medical Center Utrecht
Utrecht, Netherlands
|
| 47 |
NCT00498225 |
Completed |
Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer |
|
- Drug: Gemcitabine plus TS-1
- Drug: TS-1
- Drug: Gemcitabine
|
Interventional |
Phase 3 |
- Taiho Pharmaceutical Co., Ltd.
- TTY Biopharm
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Over all survival(OS)
- progression-free survival (PFS), response rate (RECIST, if measurable), incidence rate of adverse events, incidence rate of adverse drug reactions, QOL (EQ-5D)
|
834 |
All |
20 Years to 79 Years (Adult, Senior) |
NCT00498225 |
01023017 |
GEST |
July 2007 |
July 2011 |
June 2012 |
July 9, 2007 |
November 2, 2012 |
|
- National Cancer Center Hospital
Tokyo, Japan - Chung-Ho Memorial Hospital, Kaohsiung Medical University
No.100, Tzyou 1st Rd., Kaohsiung, Taiwan - Chang Gung Memorial Hospital, Kaohsiung
No.123, Ta-Pei Rd., Niao-Sung Hsiang, Kaohsiung Hsien, Taiwan - (and 9 more...)
|
| 48 |
NCT01494155 |
Active, not recruiting |
Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer |
|
- Drug: Capecitabine
- Drug: Hydroxychloroquine
- Radiation: Proton or Photon Radiation Therapy
|
Interventional |
Phase 2 |
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival
- Pathologic response rate
- Overall survival
- (and 8 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT01494155 |
11-073 |
|
December 2011 |
March 2019 |
January 2020 |
December 16, 2011 |
April 6, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 49 |
NCT01461915 |
Completed |
Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane |
- Metastatic Pancreatic Cancer
|
- Drug: Abraxane ( Nab-paclitaxel)
- Drug: Gemcitabine
- Drug: ODSH ( 2-O, 3-O Desulfated Heparin)
- Drug: Abraxane ( nab-paclitaxel)
|
Interventional |
Phase 2 |
- Cantex Pharmaceuticals
- Translational Drug Development
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-Free Survival (PFS) according to RECIST Guidelines.
- Incidence of Adverse Events & Toxicity [CTCAE Version 4.03]
- Overall survival (OS).
- (and 2 more...)
|
61 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01461915 |
PGX-ODSH-2011-PC1 |
PGPC1 |
November 2011 |
December 2012 |
June 2015 |
October 28, 2011 |
August 29, 2016 |
|
- Mayo Clinic Arizona
Scottsdale, Arizona, United States - Disney Family Cancer Center
Burbank, California, United States - Marin Cancer Care
Greenbrae, California, United States - (and 13 more...)
|
| 50 |
NCT01072981 |
Completed |
Immunotherapy Study for Surgically Resected Pancreatic Cancer |
|
- Biological: HyperAcute-Pancreas Immunotherapy
- Drug: Gemcitabine
- Radiation: 5FU Chemoradiation
|
Interventional |
Phase 3 |
- NewLink Genetics Corporation
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective is to assess overall survival
- The secondary objective is to assess disease free survival and to conduct correlative scientific studies of subject samples to determine the mechanism of any observed anti-tumor effect.
|
722 |
All |
18 Years and older (Adult, Senior) |
NCT01072981 |
NLG0405
OBA# 0912-1013 |
|
April 2010 |
May 2016 |
May 2016 |
February 22, 2010 |
September 21, 2016 |
|
- University of Alabama
Birmingham, Alabama, United States - University of South Alabama
Mobile, Alabama, United States - Arizona Cancer Center
Tucson, Arizona, United States - (and 70 more...)
|
Create an RSS feed from your search for:
Download the search results for: